articleThe LancetApr 20, 2017GREEN OA

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

ABAnthony B. El-KhoueiryBSBruno SangroTYThomas YauTSTodd S. CrocenziMKMasatoshi Kudo

USC Norris Comprehensive Cancer Center · Clinica Universidad de Navarra · +19 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

4,294
total citations
FWCI
180.65
Percentile
100%
References
31
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Nivolumab
  • Hepatocellular carcinoma
  • Medicine
  • Open label
  • Oncology
  • Internal medicine
  • Phase (matter)
  • Clinical trial
No related works found for this paper.